The combination of nivolumab (anti-PD-1) plus ipilimumab (anti-CTLA-4) has achieved a 10-year overall survival (OS) rate of 43% and a melanoma-specific survival (MSS) rate of 52% for patients with advanced melanoma [2]. Here, PDCD1 is linked to melanoma.